Janney On Amicus Therapeutics Also Notes 'Galafold revenue growth is encouraging', Natural history data supports superiority of AT-GAA over SOC ERT', 'Gene therapy development for Batten disease continues'

Do you like seeing these details as to why an analyst recommended a stock? What could we do to make this product better? Let us know by emailing newsdesk@benzinga.com

Benzinga · 11/11/2019 19:11